[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, ozanezumab did not show efficacy compared with placebo in patients with amyotrophic lateral sclerosis (ALS). The phase 2 trial showed that ozanezumab did not have a positive effect on function and overall survival compared to placebo. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]